KOREA ARLICO PHARM (260660) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, KOREA ARLICO PHARM (260660) reported revenue of 201.2 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025201.2 billion KRW989 million KRW-605 million KRW[source]
2024190.4 billion KRW-5.2 billion KRW-5.4 billion KRW[source]
2023187.2 billion KRW3.1 billion KRW3.1 billion KRW[source]
2022167.7 billion KRW9.9 billion KRW8.0 billion KRW[source]
2021140.2 billion KRW4.8 billion KRW4.9 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025171.8 billion KRW93.6 billion KRW78.2 billion KRW[source]
2024172.4 billion KRW92.7 billion KRW79.7 billion KRW[source]
2023173.5 billion KRW84.4 billion KRW89.1 billion KRW[source]
2022153.5 billion KRW65.0 billion KRW88.5 billion KRW[source]
2021121.1 billion KRW39.9 billion KRW81.1 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
202510.0 billion KRW-2.6 billion KRW-3.5 billion KRW[source]
2024-8.6 billion KRW4.8 billion KRW163 million KRW[source]
20237.1 billion KRW-27.3 billion KRW15.8 billion KRW[source]
20224.8 billion KRW-8.9 billion KRW18.1 billion KRW[source]
20219.0 billion KRW-6.1 billion KRW1.2 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-30 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice